NeuBase Therapeutics

NeuBase Therapeutics is an American pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. NeuBase Therapeutics is headquartered in Pittsburgh, Pennsylvania.
NeuBase Therapeutics stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

NeuBase Therapeutics balance sheet

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

NeuBase Therapeutics cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

NeuBase Therapeutics multipliers

Report period2017 2018 2019 2020 2021 2022
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

NeuBase Therapeutics profitability

Report period2017 2018 2019 2020 2021 2022
ROA
ROE
ROS
NeuBase Therapeutics assets
NeuBase Therapeutics cash flows

NeuBase Therapeutics dividend policy

The company doesn't provide dividend

NeuBase Therapeutics shares

TickerNameTypeNominal valueISINPrice
NBSE:USNeuBase TherapeuticsCommon share-US64132K1025$1.03
NeuBase Therapeutics news
13.05.2022
NeuBase Therapeutics' GAAP loss for 6 months of fiscal 2022 was $17.653 million, up 84.1% from $9.588 million in the prior year.
Source: {source} pictogram ir.neubasetherapeutics.com
Pictogram next
14.02.2022
NeuBase Therapeutics' GAAP loss for 3 months of fiscal 2022 was $7,729 million, up 90.1% from $4,066 million in the prior year. The company did not generate revenue.
Source: {source} pictogram ir.neubasetherapeutics.com
Pictogram next
16.08.2021
NeuBase Therapeutics' GAAP loss for 9M 2021 fiscal year was $18.251 million, up 43.9% from $12.684 million in the prior year.
Source: {source} pictogram ir.neubasetherapeutics.com
Pictogram next
12.02.2021
NeuBase Therapeutics GAAP loss for 3 months of fiscal year 2021 was $4.066 million, down 9.8% from $4.506 million in the previous year.
Source: {source} pictogram ir.neubasetherapeutics.com
Pictogram next
All NeuBase Therapeutics news
General information
Company nameNeuBase Therapeutics
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address700 Technology Drive Pittsburgh, PA 15219 United States
Websiteir.neubasetherapeutics.com
Information disclosurewww.sec.gov